公开(公告)号：US20250058024A1

公开(公告)日：2025-02-20

申请号：US18706336

申请日：2022-11-01

Applicant: UNIVERSITEIT MAASTRICHT ,  ACADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Matthew Brandon BAKER ,  Shahzad HAFEEZ ,  Lorenzo MORONI ,  Ana Agustina ALDANA

IPC: A61L27/52 ,  A61L27/18 ,  A61L27/38 ,  B33Y10/00 ,  B33Y70/00 ,  C07C69/76 ,  C07C205/57 ,  C07D207/46 ,  C08G65/00

Abstract: The invention describes benzene-1,3,5-tricarboxamide (BTA) based hydrogels. The hydrogels have purpose in tissue culturing for in vitro applications such as drug screening or in vivo applications such as transplantation. The hydrogels are particularly tough but still allow 3D printing and cell culturing. The invention further describes 3D printing of the hydrogels and uses of the hydrogels.

公开(公告)号：US20240309066A1

公开(公告)日：2024-09-19

申请号：US18576049

申请日：2022-06-27

Applicant: UNIVERSITEIT MAASTRICHT ,  ACADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Tim Johannes Maria WELTING ,  Guus Gijsbertus Hubert VAN DEN AKKER ,  Leon Johannes SCHURGERS ,  Lodewijk Willem VAN RHIJN

IPC: C07K14/78 ,  A61K38/00 ,  A61P19/02

CPC classification number: C07K14/78 ,  A61P19/02 ,  A61K38/00

Abstract: The invention is in the field of medical treatments, in particular the treatment of humans, more in particular humans with calcium deposition diseases. In one aspect, the invention provides polypeptides that prevent or decrease the precipitation of calcium crystals in the human body, also known as ectopic calcification. More in particular, the invention relates to a circular polypeptide consisting of an amino acid sequence according to SEQ ID NO: 1, wherein the amino acids are D-amino acids, pharmaceutical compositions comprising a polypeptide as described herein and their use in the treatment of a disease selected from the group consisting of osteoarthritis, frozen shoulder syndrome, heterotopic ossification, vascular calcification, kidney stones and calcinosis.

公开(公告)号：US11972867B2

公开(公告)日：2024-04-30

申请号：US17123816

申请日：2020-12-16

Applicant: Universiteit Maastricht

Inventor： Sebastian Sanduleanu ,  Philippe Lambin

IPC: G16H50/20 ,  G06N5/01 ,  G06N20/20 ,  G06T7/00 ,  G16H20/40 ,  G16H30/20

CPC classification number: G16H50/20 ,  G06N5/01 ,  G06N20/20 ,  G06T7/0012 ,  G16H20/40 ,  G16H30/20 ,  G06T2207/20081 ,  G06T2207/30004

Abstract: The present document describes a training method of a machine learning data processing model for determining a hypoxia status of a neoplasm, in particular a random forest model. The method comprises obtaining, for a plurality of neoplasms, at least one data sample comprising 3D imaging data. A hypoxic volume fraction is determined for each data sample, as well as a set of image features associated with the neoplasm. The method further iterates a sequence of training steps and each iteration includes: selecting a subset of image features and eliminating, for each data sample, the subset of image features to yield a reduced set of image features. The iteration also includes generating decision trees, providing a momentary random forest model based thereon, and submitting a test set of image features to the momentary random forest model to yield a performance value. The iterations are continued until all image features have been selected for a subset at least once, and then a plurality of preferred image features are selected for providing a radiomics feature signature. The trained random forest data processing model based on decision trees associated with the preferred image features of the radiomics feature signature.

公开(公告)号：US20230083417A1

公开(公告)日：2023-03-16

申请号：US17797450

申请日：2021-02-19

Applicant: Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht

Inventor： Harald Horst Heinz Wilhelm Schmidt ,  Ana Isabel Casas Guijarro

IPC: A61K31/5415 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4188 ,  A61K31/519 ,  A61K31/513 ,  A61K31/197 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/416 ,  A61P9/10

Abstract: The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.

公开(公告)号：US20210239712A1

公开(公告)日：2021-08-05

申请号：US17181390

申请日：2021-02-22

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.

公开(公告)号：US20210172962A1

公开(公告)日：2021-06-10

申请号：US17172761

申请日：2021-02-10

Applicant: Roche Diagnostics Operations, Inc. ,  UNIVERSITEIT MAASTRICHT ,  AKADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Manuel Dietrich ,  Peter Kastner ,  Vinzent Rolny ,  Ulrich Schotten ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.

公开(公告)号：US10139407B2

公开(公告)日：2018-11-27

申请号：US15095636

申请日：2016-04-11

Applicant: Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht

Inventor： Bart Robert Nicolaas Van Grinsven ,  Thomas Jan Cleij

IPC: G01N33/48 ,  G01N33/569 ,  G01N25/18 ,  G01N25/20 ,  G01N33/487 ,  G01N33/543

Abstract: A method for characterizing bacteria includes passing a liquid containing an analyte comprising a first bacteria and a second bacteria over and in contact with a polymer material on a substrate. The polymer material is formulated to bind to the first bacteria, and the first bacteria binds to the polymer material with a higher affinity than the second bacteria. A heat transfer property of the polymer material varies based on an amount of the analyte bound thereto. The method further includes binding a portion of the first bacteria and the second bacteria of the analyte to the polymer material, removing at least a portion of the second bacteria from the polymer material, detecting a temperature of the substrate, and calculating a concentration of the first bacteria in the liquid based at least in part on the temperature of the substrate.

公开(公告)号：US20170345635A1

公开(公告)日：2017-11-30

申请号：US15534958

申请日：2015-12-09

Applicant: Thermo Fisher Scientific (Bremen) GmbH ,  UNIVERSITEIT MAASTRICHT ,  UNIVERSITEIT UTRECHT HOLDING B.V.

Inventor： Alexander Alekseevich MAKAROV ,  Ronald M. A. HEEREN ,  Albert J. R. HECK

IPC: H01J49/40 ,  H01J49/00

CPC classification number: H01J49/40 ,  H01J49/0004 ,  H01J49/0036 ,  H01J49/0045

Abstract: A method of determining the structure of a macromolecular assembly (MMA) comprises the steps of (a) generating precursor ions of an MMA species to be investigated; (b) transporting the MMA precursor ions to a fragmentation zone; (c) carrying out pulsed fragmentation of the MMA precursor ions in the fragmentation zone; (d) for a first plurality of MMA precursor ions, detesting both a spatial distribution of the resultant MMA fragment ions, and an m/z distribution of the MMA fragment ions; (e) analyzing the spatial and m/z distributions of fragment ions formed from the said first plurality of precursor ions of the MMA species to be investigated, to determine the relative positions of those fragment ions within the structure of the precursor MMA; and (f) reconstructing the three dimensional (3D) structure of the MMA from the analysis of the spatial and m/z distributions of fragment ions.

公开(公告)号：US09790545B2

公开(公告)日：2017-10-17

申请号：US13864778

申请日：2013-04-17

Applicant: UNIVERSITEIT MAASTRICHT ,  Academisch Ziekenhuis Maastricht ,  Rijksinstituut Voor Volksgezondheid en Milieu

Inventor： Jeroen Lambertus Antonius Pennings ,  Petrus Theodorus Theunissen ,  Aldert Henrick Piersma

IPC: C12Q1/68

CPC classification number: C12Q1/6837 ,  C12Q1/6876 ,  C12Q2600/142

Abstract: This invention is in the field of medical molecular diagnostics. It provides methods and means for the in vitro detection of the neurodevelopmental toxicity of a compound by determining the gene expression of a limited number of genes. More in particular, it relates to a method for determining the likelihood that a compound is neurodevelopmental toxic, comprising the steps of: providing embryonic stem cells, allowing the stem cells to form embryoid bodies, allowing the embryoid bodies to differentiate into neural cells, in the presence of said compound, thereby creating a neural differentiation culture, extracting total RNA from the cells in said neural differentiation culture, determining the expression levels of genes Hoxb6, Nrk, 1700011H14Rik and Tph1, comparing the expression levels with a predetermined reference value and determining the increase or decrease of the expression level relative to the reference value, wherein a relative increase or decrease in expression value of more than 20% indicates that a compound is neurodevelopmental toxic.

公开(公告)号：US20170128623A1

公开(公告)日：2017-05-11

申请号：US15318426

申请日：2015-06-16

Applicant: Academisch Ziekenhuis Leiden ,  Xeltis B.V. ,  Universiteit Maastricht

Inventor： Joris Ivo Rotmans ,  Tonia Caroline Rothuizen ,  Lorenzo Moroni ,  Clemens Antoni Van Blitterswijk ,  Febriyani Fiain Rochel Damanik ,  Tom Lavrijsen ,  Martijn Antonius Johannes Cox ,  Antonius Johannes Rabelink

IPC: A61L27/34 ,  A61L27/54 ,  A61L27/58 ,  A61L27/18 ,  A61L27/56

CPC classification number: A61L27/34 ,  A61L27/18 ,  A61L27/36 ,  A61L27/507 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/414 ,  A61L2400/12 ,  A61L2430/22 ,  A61L2430/34 ,  C08L67/02

Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.